PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩90 per share · Prices as of the 2026-10-02 close
Innogene, a cosmeceutical company focused on hair-loss and skin-regeneration solutions, saw revenue expand sharply in the first half of 2026, but operating losses widened in tandem as marketing and new-business investment increased.
Q2 2026 revenue reached roughly KRW 4.8 billion, a sharp sequential increase, but the operating loss also widened to about KRW 530 million.
Annual operating margin fell sharply from 7.0% in 2024 to 0.1% in 2025, and the sum of the most recent four quarters shows a net loss.
The company said it plans to launch a new ampoule-embedded 'smart hairbrush' product in the second half and pursue entry into new markets including the United States and Russia.
The company continues technology-based differentiation, including a patent filing for quantitative hair-loss analysis technology and publication of an SCI paper on its mitochondrial activator composition.
Through a partnership with foodtech firm Dareumdareum, the company is expanding beyond anti-aging cosmetics and devices into functional food.
Innogene is a cosmeceutical company specializing in hair-loss care and problem-skin regeneration, providing a total solution to domestic clinics and hospitals that spans home-care cosmetics, scalp-care devices, functional foods, and pharmaceuticals.
Its core brand 'Bolvig' features a total care system combining an initial intensive therapy method (IIT) with a customized solution approach (DEDS), and the product lineup has expanded to include the male hair-loss treatment tablet Damo Care (containing finasteride), the hair-loss functional food supplement BB-Tang Plus, the scalp diagnostic device A.TRACER, and the ampoule-absorption device Cellpiers.
The problem-skin and regeneration line consists of brands such as Dr. Medixion, Rescelby, and Eveturn, which emphasize mildly acidic, low-irritation formulations.
The company's technology has helped it secure close to 5,000 domestic clinic and hospital clients along with export channels in more than 20 countries including the United States and China.
Its business model of a clinic-based B2B total solution is noted as a differentiating factor, as Innogene is described as the only listed domestic company operating this way.
Competitively, it overlaps with LG Household & Health Care, Amorepacific, and Dr.ForHair in cosmetics, and with Johnson & Johnson, AproKor, and Hanmi Pharmaceutical in pharmaceuticals.
The company recently signed a partnership with foodtech firm Dareumdareum to enter the anti-aging care-food market, and it also plans to launch a new ampoule-embedded smart hairbrush product in the second half.
In hair-loss diagnostics, it has filed a patent for anatomical-coordinate-based quantitative hair-loss analysis technology, expanding into a data-driven diagnostic platform business.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩1.9B | -₩48,187,899 | −2.5% |
| 2025Q3 | ₩2.1B | -₩29,829,398 | −1.4% |
| 2025Q4 | ₩2.4B | ₩100M | 4.5% |
| 2026Q1 | ₩2.6B | -₩200M | −6.8% |
| 2026Q2 | ₩4.8B | -₩500M | −11.0% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩9.1B | ₩1.5B | ₩1.3B | 16.3% | 19.9% | 17.9% |
| 2023 | ₩10.1B | ₩1.2B | ₩1.4B | 12.1% | 8.7% | 7.3% |
| 2024 | ₩8.9B | ₩600M | ₩900M | 7.0% | 5.7% | 5.6% |
| 2025 | ₩8.2B | ₩4,492,321 | ₩300M | 0.1% | 2.0% | 6.7% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Innogene's annual revenue rose from KRW 9.14 billion in 2022 to KRW 10.1 billion in 2023, but then declined for two consecutive years to KRW 8.94 billion in 2024 and KRW 8.21 billion in 2025.
Operating margin fell from 16.3% in 2022 and 12.1% in 2023 to 7.0% in 2024, and further to just 0.1% in 2025, effectively at breakeven. Net profit for 2025 nonetheless remained positive at KRW 288 million, which appears attributable to non-operating items such as interest income.
On a quarterly basis, operating losses of KRW 48 million in Q2 2025 and KRW 30 million in Q3 2025 were followed by a swing to profit in Q4 2025, with revenue of KRW 2.41 billion and operating profit of KRW 109 million, lifting net profit to KRW 211 million.
However, in 2026 the pattern reversed: Q1 revenue rose to KRW 2.59 billion yet the operating loss widened to KRW 176 million, and Q2 revenue jumped to KRW 4.80 billion—a large sequential increase—while the operating loss expanded further to KRW 530 million and the net loss reached KRW 472 million.
Summing the most recent four quarters (Q3 2025 through Q2 2026) yields a net loss of roughly KRW 298 million, a contrast to the full-year 2025 net profit of KRW 288 million.
This simultaneous rise in revenue and losses suggests the company is in an investment phase, increasing spending on new channels, overseas expansion, and new-product marketing.
The domestic hair-loss and anti-aging cosmeceutical market features a mix of clinic-centered B2B channels and online/home-shopping-centered B2C channels.
According to the Korea International Trade Association, Korean cosmetics exports rose 12.2% year-on-year to USD 9.4 billion in the January-October 2025 period, with the United States surpassing China as the top export destination for the first time.
Innogene exports products to more than 20 countries including the United States, China, Singapore, Hong Kong, and Malaysia amid this K-beauty export expansion, though it has previously experienced a temporary export decline due to weakness in the Chinese market.
Competition is intense, with large cosmetics companies such as LG Household & Health Care and Amorepacific, as well as pharmaceutical firms such as Johnson & Johnson and Hanmi Pharmaceutical, all holding hair-loss related product lines.
Company representatives point to differentiated ingredient formulation and mixing know-how as a competitive edge, while positioning the firm as the only domestic listed player operating a clinic-based total solution business.
Ongoing industry discussion about expanding health insurance coverage for male-pattern and M-shaped hair loss suggests that the value of quantitative diagnostic technology could grow going forward.
The company said it plans to diversify its product lineup in the second half with the launch of an ampoule-embedded smart hairbrush.
On overseas expansion, it stated that export discussions for the U.S. market are underway, an initial shipment has already been delivered to Hong Kong, and discussions with new buyers in Russia and Kazakhstan are also progressing.
In China, the company said it is pursuing a sales rebound through wanghong (Chinese social media influencer) marketing and SNS-linked sales strategies.
On business diversification, it has signed a partnership with foodtech firm Dareumdareum to jointly develop premium care-food products based on natural ingredients such as tomato and black soybean, part of a strategy to expand its portfolio from cosmetics and medical devices into ingestible anti-aging products.
On the technology front, the company has filed a patent for anatomical-coordinate-based quantitative hair-loss analysis technology and a dedicated imaging system, and said it plans to expand its data-driven diagnostic platform business using clinical feedback from roughly 4,000 nationwide client accounts.
IBK Securities noted in an earlier report that a recovery in export performance and expansion of new partnerships would be key variables for an earnings turnaround at Innogene.
Innogene's net profit has moved from a surplus toward breakeven, and most recently into a net loss on a trailing four-quarter combined basis, putting the stock in a range where conventional price-to-earnings analysis is difficult to apply.
The share price has fluctuated between a modest premium and discount relative to book value per share, generally trading within a range not far from net asset value.
On the dividend front, the company paid a cash dividend for fiscal 2025, though views on the sustainability of that payout may differ given recent earnings weakness.
As the company is simultaneously expanding revenue and losses, the timing and pace at which current investment spending converts into revenue and margin improvement are likely to be key variables in any valuation assessment.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Discussions are underway to enter new markets such as the United States and Russia, and an initial shipment has already been delivered to Hong Kong. In China, the company is pursuing a sales rebound through wanghong influencer marketing. The strategy builds on an existing export network spanning more than 20 countries.
A paper on the company's mitochondrial activator composition was published in an international SCI-indexed journal, and it has also filed a patent for quantitative hair-loss analysis technology.
It is seeking to expand into a data-driven diagnostic platform business using clinical feedback from roughly 4,000 client accounts.
Through its partnership with Dareumdareum, the company is entering the anti-aging care-food market, moving beyond its existing cosmetics- and device-centered business. It also plans to strengthen its home-care device lineup with the launch of a new smart hairbrush in the second half.
Annual operating margin fell sharply from 7.0% in 2024 to 0.1% in 2025, and operating losses continued in both the first and second quarters of 2026, with the loss size actually widening. Profitability improvement has not followed even as revenue has grown.
Annual revenue peaked at KRW 10.1 billion in 2023 before declining for two consecutive years to KRW 8.94 billion in 2024 and KRW 8.21 billion in 2025. A broad contraction across both domestic and export sales structures has been cited as a factor increasing the fixed-cost burden.
The company has previously experienced a temporary export decline due to weakness in the Chinese market, and securities analysts have pointed to export recovery as a key variable for earnings improvement.
Entry into new markets such as the United States and Russia remains at the discussion stage, leaving outcomes uncertain.
Increased spending on marketing and R&D has driven revenue growth, but the timing of a shift to improved profitability has not yet been confirmed. If such investment continues, losses could widen further.
Large cosmetics and pharmaceutical companies hold numerous hair-loss related product lines, making market competition intense. A company representative has described the hair-loss market as a 'red ocean,' acknowledging the difficulty of differentiation.
Discussion of expanding health insurance coverage for male-pattern and M-shaped hair loss is ongoing, and related policy changes could affect market structure and the competitive landscape. Changes in cosmetics and medical device approval regulations are also a factor that could affect the business.
The Q3 2026 quarterly report is due around this time; it will be important to check whether operating losses continue to widen or begin to narrow following the trend seen in Q1 and Q2.
This is the time to check the launch and early sales performance of the new ampoule-embedded smart hairbrush, as well as concrete progress on U.S. export discussions.
It will be worth checking whether the care-food products jointly developed with Dareumdareum are launched and how much they contribute to new revenue.
The progress of discussions on expanding health insurance coverage for male-pattern and M-shaped hair loss should be monitored, as it could affect the value of the company's diagnostic platform business.
This is when the FY2026 annual business report and audit report are due, allowing confirmation of how the widened first-half losses affected full-year results.
Innogene is expanding its domestic and overseas channels based on a differentiated clinic-based total solution model for hair-loss and skin-regeneration care, but since 2025 its operating margin has fallen sharply, and in the first half of 2026 revenue growth and widening operating losses have occurred simultaneously.
The company has outlined plans to broaden its revenue base through new product launches, entry into new markets such as the United States and Russia, and diversification into care food, while continuing technology differentiation efforts such as its quantitative hair-loss diagnostic patent.
However, it remains unconfirmed when this investment will translate into improved profitability, and profitability metrics have weakened, with a net loss recorded on a trailing four-quarter combined basis.
Competition from large cosmetics and pharmaceutical companies, dependence on specific export markets such as China, and policy variables such as expanded health insurance coverage also warrant attention.
Ahead of any investment decision, it appears important to monitor the upcoming Q3 and annual earnings disclosures as well as concrete results from new markets and new products.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.